Compositions and methods for transdermal delivery of tertiary amine drugs
Described are transdermal drug delivery systems for the transdermal administration of tertiary amine drugs, such as rivastigmine, fentanyl or rotigotine, comprising a polymer matrix comprising a free base form of the drug and at least one carboxyl group-containing compound. In some embodiments, the systems include a rate-controlling membrane and a skin-contacting face adhesive apart from the polymer matrix.
1. A transdermal drug delivery system comprising:
a polymer matrix formed by blending the free base form of a tertiary amine drug and at least one carboxyl group-containing compound, wherein the relative amounts of free base and carboxyl group-containing compound is such that greater than 50% of the free base is associated with a carboxylic acid group to form a salt, and
a backing layer,
wherein the transdermal drug delivery system releases drug upon application to skin, and is effective to deliver a therapeutically effective amount of the tertiary amine drug through skin for at least 3 days.
2. The transdermal drug delivery system according to claim 1 , wherein the relative amounts of free base and carboxyl group-containing compound is such that at least 60% of the free base is associated with a carboxylic acid group to form a salt.
3. The transdermal drug delivery system according to claim 1 , wherein the relative amounts of free base and carboxyl group-containing compound is such that at least 70% of the free base is associated with a carboxylic acid group to form a salt.
4. The transdermal drug delivery system according to claim 1 , wherein the relative amounts of free base and carboxyl group-containing compound is such that at least 80% of the free base is associated with a carboxylic acid group to form a salt.
5. The transdermal drug delivery system according to claim 1 , wherein the relative amounts of free base and carboxyl group-containing compound is such that at least 90% of the free base is associated with a carboxylic acid group to form a salt.
6. The transdermal drug delivery system according to claim 1 , wherein the relative amounts of free base and carboxyl group-containing compound is such that about 100% of the free base is associated with a carboxylic acid group to form a salt.
7. The transdermal drug delivery system according to claim 1 , wherein at least one carboxyl group-containing compound is a carrier polymer comprising carboxy-functional groups.
8. The transdermal drug delivery system according to claim 1 , wherein at least one carboxyl group-containing compound is an acrylic pressure-sensitive adhesive polymer comprising carboxy-functional groups.
9. The transdermal drug delivery system according to claim 1 , wherein at least one carboxyl group-containing compound is a polymeric carboxylic acid.
10. The transdermal drug delivery system according to claim 9 , wherein the polymeric carboxylic acid is selected from the group consisting of anionic copolymers based on methacrylic acid and methyl methacrylate, carbomer polymers, carbopol polymers, vinyl polymers containing carboxylic acid groups, carboxyl group-containing cellulose polymers and carboxyl group-containing starches.
11. The transdermal drug delivery system according to claim 1 , wherein the tertiary amine drug is selected from the group consisting of amiodarone, amitriptyline, atropine, benztropine, biperiden, bornaprine, bupivacaine, chlorpheniramine, cinnarizine, clomipramine, cyclopentolate, darifenacin, dexetimide, dicyclomine, diltiazem, diphenhydramine, doxepin, ethopropazine, fentanyl, flavoxate, homatropine, imipramine, loxapine, mazaticol, metixene, oxybutin, oxyphencyclimine, phenglutarimide, physostigmine, piperidolate, pirenzepine, procyclidine, profenamine, propiverine, rivastigmine, rotogotine, scopolamine, telenzepine, theophylline, tolterodine, trimipramine, trihexyphenidyl, tropatepine, tropicamide, and rivastigmine.
12. The transdermal drug delivery system according to claim 1 , wherein the composition does not include a penetration enhancer comprising a carboxylic acid group.
13. The transdermal drug delivery system according to claim 1 , wherein the composition does not include a monocarboxylic fatty acid.
14. The transdermal drug delivery system according to claim 1 , wherein the polymer matrix further comprises an antioxidant.
15. The transdermal drug delivery system according to claim 1 , wherein the polymer matrix further comprises a plasticizer.
16. The transdermal drug delivery system according to claim 1 , wherein the polymer matrix comprises:
about 10% to about 40% by weight of a free base form of the tertiary amine drug;
about 0% to about 90% by weight of a carrier polymer, optionally containing carboxyl-group containing carboxy-functional groups;
about 0% to about 90% by weight of a carboxyl group-containing compound;
optionally, about 0% to about 1% of an antioxidant; and
optionally, about 0% to about 20% of a pharmaceutically acceptable excipient,
wherein the relative amounts of free base and carboxyl groups is such that greater than 50% of the free base is associated with a carboxylic acid group to form a salt.
17. The transdermal drug delivery system according to claim 1 , wherein the system is effective to deliver a therapeutically effective amount of tertiary amine drug through skin over a period of time selected from the group consisting of at least 4 days, at least 5 days, at least 6 days and at least 7 days.
18. The transdermal drug delivery system according to claim 1 , wherein the tertiary amine drug is rivastigmine and the system is effective to deliver through skin (i) at least about 4.6 mg/day over a period of time selected from the group consisting of at least 3 days, at least 4 days, at least 5 days, at least 6 days and at least 7 days or (ii) at least about 9.5 mg/day over a period of time selected from the group consisting of at least 3 days, at least 4 days, at least 5 days, at least 6 days and at least 7 days.
19. The transdermal drug delivery system according to claim 1 , wherein the polymer matrix has a coat weight of about 10-15 mg/cm 2 .
20. A method for administering a tertiary amine drug, comprising applying to the skin of a subject in need thereof a transdermal drug delivery system according to claim 1 .
21. A method of making a transdermal drug delivery system for a tertiary amine drug, comprising:
forming a polymer matrix by blending a free base form of the tertiary amine drug and at least one carboxyl group-containing compound, wherein the relative amounts of free base and carboxyl group-containing compound is such that greater than 50% of the free base is associated with a carboxylic acid group to form a salt, and
wherein the transdermal drug delivery system releases drug upon application to skin, and is effective to deliver a therapeutically effective amount of the tertiary amine drug through skin for at least 3 days.
22. A transdermal drug delivery system comprising a polymer matrix comprising the free base form of a tertiary amine drug, a rate-controlling membrane, and a face adhesive comprising a carboxyl group-containing compound, wherein the rate controlling membrane is disposed between the polymer matrix and the face adhesive, and wherein the system is effective to deliver a therapeutically effective amount of the tertiary amine drug through skin for at least 3 days.
23. The transdermal drug delivery system according to claim 22 , wherein the rate-controlling membrane comprises a polymer selected from the group consisting of polyethylene, polyolefin, and/or ethylene vinyl acetate polymers.
24. The transdermal drug delivery system according to claim 22 , wherein the polymer matrix comprises a polymer selected from the group consisting of acrylic polymers, silicone polymers, polyisobutylene polymers, styrene-isoprene styrene block copolymers, and mixtures of two or more thereof.
25. The transdermal drug delivery system according to claim 22 , wherein the face adhesive comprises a polymer selected from the group consisting of acrylic polymers, silicone polymers, and mixtures of two or more thereof.
26. The transdermal drug delivery system according to claim 22 , wherein the system is effective to deliver a therapeutically effective amount of tertiary amine drug through skin over a period of time selected from the group consisting of at least 4 days, at least 5 days, at least 6 days and at least 7 days.
27. The transdermal drug delivery system according to claim 22 , wherein the tertiary amine drug is rivastigmine and the system is effective to deliver through skin (i) at least about 4.6 mg/day over a period of time selected from the group consisting of at least 3 days, at least 4 days, at least 5 days, at least 6 days and at least 7 days or (ii) at least about 9.5 mg/day over a period of time selected from the group consisting of at least 3 days, at least 4 days, at least 5 days, at least 6 days and at least 7 days.
28. The transdermal drug delivery system according to claim 22 , wherein the polymer matrix has a coat weight of about 10-15 mg/cm 2 .
29. A method for transdermally administering a tertiary amine drug through skin, comprising applying to the skin of a subject in need thereof a transdermal drug delivery system according to claim 22 .
30. A method of making a transdermal drug delivery system for a tertiary amine drug, comprising combining
a polymer matrix comprising a free base form of the tertiary amine drug in an amount effective to deliver a therapeutically effective amount of the tertiary amine drug through skin for at least 3 days;
a rate-controlling membrane; and
a face adhesive comprising a carboxyl group-containing compound
wherein the rate controlling membrane is disposed between the polymer matrix and the face adhesive, and wherein the system is effective to deliver a therapeutically effective amount of the tertiary amine drug through skin for at least 3 days.
31. The transdermal drug delivery system according to claim 1 , wherein the tertiary amine drug is rivastigmine and the polymer matrix includes an amount of rivastigmine selected from about 32-65 mg and about 67-126 mg.
32. The transdermal drug delivery system according to claim 22 , wherein the tertiary amine drug is rivastigmine and the polymer matrix includes an amount of rivastigmine selected from about 32-65 mg and about 67-126 mg.